129 related articles for article (PubMed ID: 7747710)
1. Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder.
Pronzato P; Landucci M; Vaira F; Vigani A; Bertelli G
Am J Clin Oncol; 1995 Jun; 18(3):223-5. PubMed ID: 7747710
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial.
Boccardo F; Pace M; Guarneri D; Canobbio L; Curotto A; Martorana G
Cancer; 1994 Apr; 73(7):1932-6. PubMed ID: 8137220
[TBL] [Abstract][Full Text] [Related]
3. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Small EJ; Fippin LJ; Ernest ML; Carroll PR
Cancer; 1996 Oct; 78(8):1775-80. PubMed ID: 8859191
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma.
Solá C; Mallafré J; Mendoza Solórzano L; Segarra A; Daniels M; Viñolas N; Alcaraz A; Solé M; Alvarez R; Biete A
Ann Oncol; 1993 Apr; 4(4):313-6. PubMed ID: 8518222
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study.
Skarlos DV; Aravantinos G; Linardou E; Kostakopoulos CA; Kastriotis I; Christodoulou C; Picramenos D; Giannakakis T; Dimopoulos K; Fountzilas G
Eur Urol; 1997; 31(4):420-7. PubMed ID: 9187901
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin).
Lorusso V; Pagliarulo A; Selvaggi FP; Durini E; Riccardi F; Comella P; Fiorillo C; De Lena M
J Chemother; 1996 Apr; 8(2):154-8. PubMed ID: 8708748
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with methotrexate, carboplatin, mitoxantrone (Novantrone) and vincristine (Oncovin) in transitional-cell urothelial cancer.
Pectasides D; Mylonakis A; Antoniou F; Kostopoulou M; Triantaphyllis D; Papadopoulou M; Varthalitis J; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(2):139-44. PubMed ID: 9499188
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
10. First-line chemotherapy with cisplatin, methotrexate and vinblastine in metastatic bladder cancer.
Pajk B; Cufer T; Cervek J; Zakotnik B
Tumori; 1996; 82(5):453-5. PubMed ID: 9063522
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
12. New combination chemotherapy programme for bladder cancer.
Waxman J; Abel P; James N; Farah N; O'Donoghue EP; Mee D; Colbeck R; Sikora K; Williams G
Br J Urol; 1989 Jan; 63(1):68-71. PubMed ID: 2920263
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
14. M-VECA (methotrexate, vinblastine, epidoxorubicin and carboplatin) in the treatment of advanced urothelial carcinoma.
Lorusso V; Berardi F; Brandi M; Mastria A; Paradiso A; Catino AM; Tatulli C; De Lena M
Tumori; 1993 Jun; 79(3):191-4. PubMed ID: 8236502
[TBL] [Abstract][Full Text] [Related]
15. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
[TBL] [Abstract][Full Text] [Related]
16. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study.
de la Rosa F; Garcia-Carbonero R; Passas J; Rosino A; Lianes P; Paz-Ares L
J Urol; 2002 Jun; 167(6):2413-8. PubMed ID: 11992048
[TBL] [Abstract][Full Text] [Related]
17. M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.
Bellmunt J; Ribas A; Albanell J; Bermejo B; Vera R; De Torres JA; Morote J; Lopez-Pacios MA; Banus JM; Rovirosa A; Carulla J; Sole LA
Am J Clin Oncol; 1996 Aug; 19(4):344-8. PubMed ID: 8677901
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.
Mead GM; Russell M; Clark P; Harland SJ; Harper PG; Cowan R; Roberts JT; Uscinska BM; Griffiths GO; Parmar MK
Br J Cancer; 1998 Oct; 78(8):1067-75. PubMed ID: 9792152
[TBL] [Abstract][Full Text] [Related]
19. CMV front-line chemotherapy in transitional bladder carcinoma.
Paz-Ares L; Lianes P; Díaz-Puente M; Rivera F; Passas J; Costas P; Mendiola C; Cortés-Funes H
Ann Oncol; 1993 Feb; 4(2):147-50. PubMed ID: 8448083
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.
Bellmunt J; Albanell J; Gallego OS; Ribas A; Vicente P; Carulla J; De Torres J; Morote J; Lopez M; Solé LA
Cancer; 1992 Oct; 70(7):1974-9. PubMed ID: 1525774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
